GSK Acquires Vaccine Platform Tech Company Okairos - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Acquires Vaccine Platform Tech Company Okairos


GlaxoSmithKline (GSK announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for $325 million, the company stated in a press release. Swiss-based Okairos is a private company that has developed a novel vaccine platform technology that is expected to play an important role in GSK’s development of new prophylactic vaccines (designed to prevent infection) as well as new classes of therapeutic vaccines (designed to treat infection or disease). GSK states that Okairos’ technology complements GSK’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines. The deal also includes a small number of early stage assets.

Under the terms of the transaction, GSK will take full ownership of Okairos and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus (RSV), hepatitis C virus (HCV), malaria, tuberculosis, ebola, and HIV, supplementing the company’s existing vaccines pipeline. Okairos’ platform technology is based on novel viral vectors (mechanisms which deliver genetic material into cells) that are designed to help stimulate immune responses (in particular T-cells) and aim to protect against and treat infectious diseases and cancer. The potential of this technology has been tested in clinical studies in which more than 700 subjects have been vaccinated, including Phase II programs in hepatitis C and malaria.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here